PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28529312-0 2017 Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Dexamethasone 69-82 IKAROS family zinc finger 1 Homo sapiens 21-26 34492683-4 2021 IKZF1 knockout and heterozygous null cells displayed relative resistance to a number of common therapies for B-ALL including dexamethasone, asparaginase, and daunorubicin. Dexamethasone 125-138 IKAROS family zinc finger 1 Homo sapiens 0-5 28052520-0 2017 IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma. Dexamethasone 114-127 IKAROS family zinc finger 1 Homo sapiens 0-6 24914135-8 2014 Clinical relevance of CRBN-binding proteins was demonstrated in 44 refractory MM patients treated with pomalidomide and dexamethasone therapy in whom low IKZF1 gene expression predicted lack of response (0/11 responses in the lowest expression quartile). Dexamethasone 120-133 IKAROS family zinc finger 1 Homo sapiens 154-159 20445578-5 2010 A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Dexamethasone 100-113 IKAROS family zinc finger 1 Homo sapiens 190-195